CRBU
What one share of Caribou Biosciences holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (“CRISPR”) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.
Caribou Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.10 |
|---|---|
| Profit | −$1.08 |
| Capex (buildings and equipment) | −$0.00 |
| Free cash flow | −$1.00 |
| Cash and investments | $0.25 |
| Book value | $0.93 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.69 | −$2.80 | $0.11 | −$3.93 | — | $0.89 |
| 2020 | $1.45 | −$4.01 | $0.04 | −$3.92 | — | −$2.41 |
| 2021 | $0.30 | −$2.11 | $0.07 | −$1.09 | — | $6.44 |
| 2022 | $0.23 | −$1.64 | $0.11 | −$1.60 | — | $4.93 |
| 2023 | $0.47 | −$1.38 | $0.16 | −$1.42 | — | $4.17 |
| 2024 | $0.11 | −$1.65 | $0.05 | −$1.58 | — | $2.74 |
| 2025 | $0.12 | −$1.59 | $0.01 | −$1.20 | — | $1.28 |